Understanding the Category I–IV and GRADE framework that governs therapeutic apheresis decisions — and a 2026 evidence quality analysis of the full ASFA guideline corpus.
The American Society for Apheresis (ASFA) is the premier professional organization for therapeutic apheresis practitioners. Since 1985, ASFA has published periodic evidence-based guidelines classifying therapeutic apheresis indications, providing clinicians worldwide with a standardized, peer-reviewed framework for treatment decisions.
ASFA guidelines are developed by a multidisciplinary expert panel using systematic literature review and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. Each edition expands and refines the evidence base, classifying therapeutic apheresis indications across a broad range of diseases and conditions.
Each indication is assigned two ratings: a Category (I through IV) describing the clinical role of apheresis, and a Grade (1A through 2C) reflecting the strength of the recommendation and the quality of underlying evidence.
The Category rating describes the clinical role of apheresis — whether it is first-line, second-line, uncertain, or contraindicated. This is distinct from the grade, which describes the strength of evidence.
Category I indicates that apheresis is accepted as first-line therapy, either as a standalone treatment or in conjunction with other therapies. The evidence and clinical experience strongly support routine use in most or all patients with the condition. Clinical guidelines, textbooks, and standard of care typically recommend apheresis as the primary intervention.
Category II indicates that apheresis is accepted as a second-line therapy — used when first-line treatments have failed, are contraindicated, or in combination with primary therapies. The evidence supports use, but other treatments are generally tried first. Apheresis plays an important supportive or adjunctive role.
Category III indicates that the optimum role of apheresis has not been established. Available evidence is insufficient, conflicting, or limited to case reports and small series. Use of apheresis in these conditions requires individualized decision-making based on clinical circumstances, patient preferences, available alternatives, and the judgment of the treating clinician. Participation in clinical trials is encouraged.
Category IV is assigned when published evidence demonstrates or suggests that apheresis is ineffective or may cause harm in the specified condition. IRB approval is strongly recommended before undertaking apheresis in these settings. These ratings represent an important evidence-based brake on inappropriate utilization.
Note: ASFA periodically retires indications to Category IV as evidence accumulates. This reflects an ongoing evidence-based process of refinement — not all previously studied uses have proven effective.
Example: SLE nephritis (lupus nephritis) was downgraded based on controlled trial evidence showing no benefit of TPE over standard immunosuppressive therapy alone.
ASFA uses the GRADE methodology to assign each indication two scores: strength of recommendation (1 = strong, 2 = weak) and quality of evidence (A = high, B = moderate, C = low). These combine into grades from 1A (strongest) to 2C (weakest).
Can be applied to most patients in most circumstances without reservation. Benefits clearly outweigh risks. Clinicians should follow unless there is a clear and compelling rationale for an alternative approach.
Best action may differ depending on individual patient circumstances and values. Clinicians must help patients make decisions consistent with their own values and preferences.
Consistent evidence from multiple well-conducted randomized controlled trials (RCTs) with >100 patients. Further research unlikely to change confidence in effect estimate.
Evidence from controlled trials with some limitations, or from observational studies with very strong evidence. Further research may change estimates.
Evidence from case series (>10 patients) or case reports (<10). Very uncertain estimates; further research is very likely to change conclusions.
| Grade | Strength | Evidence Quality | Evidence Type | Clinical Implication |
|---|---|---|---|---|
| 1A | Strong | High | Multiple high-quality RCTs | Apply to virtually all patients. Strong recommendation in any evidence-based clinical setting. |
| 1B | Strong | Moderate | RCTs with limitations or strong observational | Apply to most patients. Recommendation will apply in most clinical contexts. |
| 1C | Strong | Low | Case series / observational | Apply to most patients but subject to change if better evidence emerges. |
| 2A | Weak | High | High-quality RCTs | Best action differs by patient values. Even with good evidence, uncertainty exists about benefit-harm balance. |
| 2B | Weak | Moderate | RCTs with limitations | Best action depends on circumstances. Alternative approaches may be equally reasonable. |
| 2C | Weak | Low | Case series / case reports | Very weak recommendation. Other alternatives may be equally or more appropriate. Clinical judgment essential. |
Important Context: A strong recommendation (Grade 1) reflects confidence in the benefit-risk balance, not necessarily strong evidence. A Grade 1C means: "We are strongly confident apheresis should be used, even though the evidence is low-quality (case series)." Many rare diseases simply cannot generate high-quality RCT evidence due to small patient populations.
Seven new disease conditions added to the guidelines, reflecting emerging evidence for apheresis in conditions not previously covered. Includes new autoimmune and rare disease categories.
Eight existing indications were recategorized based on new clinical trial data. Some conditions moved from Category II to I; others moved from I/II to III based on updated evidence.
Ten previously listed indications were retired to Category IV — evidence now suggests ineffectiveness or harm. This reflects the ongoing, evidence-driven evolution of clinical practice in apheresis.
The most recent edition updated terminology for several condition categories to align with current medical understanding and ICD classification:
A February 2026 analysis published in the Journal of Clinical Apheresis examined the full corpus of ASFA guideline indications and found a striking pattern: only 8% of ASFA indications are supported by high-quality evidence (Grade A), yet one-third carry strong recommendations (Grade 1). This is not a flaw in the guidelines — it is a reflection of the unique clinical reality of therapeutic apheresis.
Understanding why strong recommendations can coexist with low-quality evidence is essential for any clinician or patient trying to interpret apheresis guidelines accurately.
Grade A (RCT-level) evidence supports only 8% of all ASFA indications
Over one-third of indications carry Grade 1 (strong) recommendations despite low evidence quality
Analyzed across the full ASFA guideline corpus
Journal of Clinical Apheresis, February 2026
The GRADE system was designed for common diseases where large RCTs are feasible. Therapeutic apheresis operates in a fundamentally different environment. Most apheresis indications involve rare diseases where enrolling hundreds of patients in a placebo-controlled trial is ethically and logistically impossible.
Consider TTP: withholding plasma exchange from a patient with TTP to conduct a placebo-controlled trial would be unethical given the >90% mortality without treatment. The evidence is Grade C (case series), but the recommendation is Grade 1 (strong) because the benefit-harm calculation is unambiguous.
The 2026 JCA analysis authors explicitly note that the low proportion of Grade A evidence does not indicate that ASFA guidelines are unreliable — it indicates that the field operates in a domain where RCT evidence is structurally difficult to generate, and that expert consensus informed by pathophysiological reasoning and observational data is the appropriate standard.
Many apheresis indications affect fewer than 1 in 100,000 people. Multicenter RCTs require years and substantial funding that rarely materializes for rare diseases.
For conditions like TTP, GBS, and anti-GBM disease, withholding apheresis in a control arm is ethically impermissible given the severity of outcomes without treatment.
Strong mechanistic rationale (e.g., removing a known pathogenic antibody) can justify a strong recommendation even when RCT evidence is absent, particularly when the disease is severe and alternatives are limited.
| Evidence Grade | Evidence Quality | Approx. % of Indications | Clinical Interpretation |
|---|---|---|---|
| A | High (RCT-level) | ~8% | Multiple consistent RCTs. High confidence in effect estimate. Examples: TTP (1A), GBS (1A), HoFH (1A). |
| B | Moderate | ~22% | RCTs with limitations, or strong observational data. Examples: CIDP (1B), Anti-GBM (1B), CTCL/ECP (1B). |
| C | Low (Case series) | ~70% | Case series and reports. Majority of rare disease indications. Does not mean ineffective — means evidence is limited by disease rarity and ethical constraints. |
Key Takeaway for Clinicians: A Grade 2C rating does not mean apheresis is ineffective — it means the evidence base is limited, typically because the disease is rare and RCTs are not feasible. Clinical judgment, pathophysiological reasoning, and individualized patient assessment remain essential. The ASFA category (I–IV) and the GRADE score serve different functions and must be interpreted together.
Connelly-Smith L, Alquist CR, Aqui NA, et al. · American Society for Apheresis · Journal of Clinical Apheresis, 2023;38(2):77–278 · PubMed 37017433
✓ Free Full Text — Wiley Online Library
The definitive global reference for therapeutic apheresis indications. Covers a comprehensive range of diseases and conditions using the ASFA Category (I–IV) and GRADE methodology. Developed by a multidisciplinary expert panel with systematic literature review. This is the primary basis for all disease entries on this website.
Confirm the diagnosis and identify the specific clinical scenario (acute vs. chronic, first-line vs. refractory). Multiple ASFA categories may exist for a single disease depending on the indication.
Category determines clinical role (first-line, second-line, uncertain). Grade determines how confident to be in that role. Category I + Grade 1A is the strongest combination; Category III + Grade 2C warrants the most individualized judgment.
Vascular access, comorbidities, concurrent medications (antibiotics removed by TPE), coagulation status, allergies to replacement fluids, and patient/family values all influence procedure choice.
Choose procedure type (TPE, RBC exchange, ECP, LDL apheresis, etc.), replacement fluid, anticoagulation, plasma volumes, frequency, and duration based on condition-specific protocols.
Establish what constitutes response, how to monitor (lab markers, clinical improvement), and pre-specified stopping criteria — both for response and for futility.
Guideline Limitation: ASFA guidelines reflect population-level evidence at the time of publication. A Category III rating does not mean apheresis won't help an individual patient — it means population-level evidence is insufficient to make a blanket recommendation. Clinical judgment remains paramount.
All references verified February 2026. DOIs and PubMed IDs confirmed against publisher records. Links open in a new tab.
Primary Sources — All Clinical Content Derived From These